Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Oct;85(8):1124–1129. doi: 10.1054/bjoc.2001.2014

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

H Gelderblom 1,5, A Sparreboom 1, M J A de Jonge 1, W J Loos 1, E Wilms 2, M A Mantel 1, B Hennis 3, I Camlett 4, J Verweij 1, M E L van der Burg 1
PMCID: PMC2375148  PMID: 11710824

Abstract

Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly haematologic. Since preclinical data suggest that Cremophor EL (CrEL), the formulation vehicle of paclitaxel, has a protective effect on haematological toxicity of cisplatin, CrEL was added to the combination cisplatin and topotecan. In this phase I study, escalating doses of oral topotecan administered on day 1, 2, 8, 9, 15, 16, 29, 30, 36, 37, 43, 44 were combined with weekly cisplatin 70 mg m−2d−1on day 1, 8, 15, 29, 36, 43 (scheme A) or with the presumably less myelotoxic sequence weekly cisplatin day 2, 9, 16, 30, 37, 44 (scheme B). In scheme C, CrEL 12 ml was administered prior to cisplatin in the sequence of Scheme A. 18 patients have received a total of 85 courses. In scheme A 4/10 patients, all treated with topotecan 0.45 mg m−2d−1, experienced DLT: 1 patient had vomiting grade 4, 1 patient had grade 4 neutropenia >5 days, 1 patient had >2 weeks delay due to thrombocytopenia and 1 patient due to neutropenia. Both patients in scheme B (topotecan 0.45 mg m−2d−1) had DLT due to a delay > 2 weeks because of prolonged haematological toxicity. No DLT was observed in the first 3 patients in scheme C (topotecan 0.45 mg m−2d−1). However, 2 out of 3 patients treated at dose level topotecan 0.60 mg m−2d−1in scheme C experienced DLT due to >2 weeks delay because of persistent thrombocytopenia or neutropenia. We conclude that there is a modest clinical effect of CrEL on haematological toxicity for this cisplatin-based combination regimen, which seems to reduce these side effects but does not really enable an increase of the oral topotecan dose. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: cisplatin, oral topotecan, cremophor EL, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (61.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badary O. A., Abdel-Naim A. B., Khalifa A. E., Hamada F. M. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):339–344. doi: 10.1007/s002109900193. [DOI] [PubMed] [Google Scholar]
  2. Chou T. C., Motzer R. J., Tong Y., Bosl G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994 Oct 19;86(20):1517–1524. doi: 10.1093/jnci/86.20.1517. [DOI] [PubMed] [Google Scholar]
  3. Ciesielski-Carlucci C., Leong P., Jacobs C. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Am J Clin Oncol. 1997 Aug;20(4):373–375. doi: 10.1097/00000421-199708000-00010. [DOI] [PubMed] [Google Scholar]
  4. Gelderblom A. J., Loos W. J., de Jonge M. J., Sparreboom A., Planting A. S., van der Burg M. E., Brouwer E., Verheij C., Ouwens L., Hearn S. Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin. Ann Oncol. 2000 Sep;11(9):1205–1207. doi: 10.1023/a:1008396414915. [DOI] [PubMed] [Google Scholar]
  5. Gerrits C. J., Burris H., Schellens J. H., Planting A. S., van den Burg M. E., Rodriguez G. I., van Beurden V., Loos W. J., Hudson I., Fields S. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer. 1998 Jun;34(7):1030–1035. doi: 10.1016/s0959-8049(97)10173-3. [DOI] [PubMed] [Google Scholar]
  6. Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., Wernz J., Chachoua A., Raphael B., Vinci R. Z. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 1994 Mar;12(3):553–559. doi: 10.1200/JCO.1994.12.3.553. [DOI] [PubMed] [Google Scholar]
  7. Liu G., Franssen E., Fitch M. I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997 Jan;15(1):110–115. doi: 10.1200/JCO.1997.15.1.110. [DOI] [PubMed] [Google Scholar]
  8. Ma J., Verweij J., Planting A. S., Kolker H. J., Loos W. J., de Boer-Dennert M., van der Burg M. E., Stoter G., Schellens J. H. Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol. 1996;37(4):382–384. doi: 10.1007/s002800050401. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. P., Ozols R. F. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998 Jun;25(3):340–348. [PubMed] [Google Scholar]
  10. Miller A. A., Hargis J. B., Lilenbaum R. C., Fields S. Z., Rosner G. L., Schilsky R. L. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec;12(12):2743–2750. doi: 10.1200/JCO.1994.12.12.2743. [DOI] [PubMed] [Google Scholar]
  11. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5–27. doi: 10.3322/canjclin.47.1.5. [DOI] [PubMed] [Google Scholar]
  12. Romanelli S., Perego P., Pratesi G., Carenini N., Tortoreto M., Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 1998;41(5):385–390. doi: 10.1007/s002800050755. [DOI] [PubMed] [Google Scholar]
  13. Rowinsky E. K., Kaufmann S. H., Baker S. D., Grochow L. B., Chen T. L., Peereboom D., Bowling M. K., Sartorius S. E., Ettinger D. S., Forastiere A. A. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol. 1996 Dec;14(12):3074–3084. doi: 10.1200/JCO.1996.14.12.3074. [DOI] [PubMed] [Google Scholar]
  14. Swisher E. M., Mutch D. G., Rader J. S., Elbendary A., Herzog T. J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep;66(3):480–486. doi: 10.1006/gyno.1997.4787. [DOI] [PubMed] [Google Scholar]
  15. Thigpen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994 Sep;12(9):1748–1753. doi: 10.1200/JCO.1994.12.9.1748. [DOI] [PubMed] [Google Scholar]
  16. de Jonge M. J., Loos W. J., Gelderblom H., Planting A. S., van der Burg M. E., Sparreboom A., Brouwer E., van Beurden V., Mantel M. A., Doyle E. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol. 2000 May;18(10):2104–2115. doi: 10.1200/JCO.2000.18.10.2104. [DOI] [PubMed] [Google Scholar]
  17. de Vos A. I., Nooter K., Verweij J., Loos W. J., Brouwer E., de Bruijn P., Ruijgrok E. J., van der Burg M. E., Stoter G., Sparreboom A. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol. 1997 Nov;8(11):1145–1150. doi: 10.1023/a:1008215720081. [DOI] [PubMed] [Google Scholar]
  18. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183–2193. doi: 10.1200/JCO.1997.15.6.2183. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES